Introduction
Cell cycle progression in normal cells involves a tightly orchestrated series of events involving cyclin-dependent kinases (Cdk), cyclins and Cdk inhibitor proteins (Sherr and Roberts, 1999) . In the G1 phase, growth factor and integrin-mediated signals cooperate to regulate retinoblastoma (Rb) hyperphosphorylation through the induction of D-type cyclins leading to activation of Cdk4/6, and via downregulation of the Cdk2 inhibitors, p27
Kip1 and p21 Cip1 (Assoian and Schwartz, 2001 ). Hyperphosphorylation and inactivation of Rb by Cdk4/6-cyclin D and Cdk2-cyclin E complexes leads to enhanced E2F transcription factor activity at the promoter sites of genes that are required for entry into S phase (Harbour and Dean, 2000) .
A common feature of malignant transformation is dysregulation of G1 cell cycle events (Hanahan and Weinberg, 2000) . Cancer cells show a reduced requirement for growth factors and matrix adhesion that may occur via multiple mechanisms. Cdk4/6 activities are frequently increased in tumors owing to amplification of cyclin D1 and inactivating mutations in the Cdk4/6 inhibitor, p16 INK4a . Also, growth factor and adhesionregulated pathways such as the extracellular signalregulated kinase (ERK)1/2 and phosphatidylinositol-3 (PI-3) kinase/Akt pathways, which control cyclin D1 and p27 Kip1 expression, are frequently upregulated (Assoian and Schwartz, 2001) . Levels of p27
Kip1 may be regulated at the level of mRNA, translation and through ubiquitin-dependent proteasomal degradation.
Degradation of p27
Kip1 involves the Skp1/Cul1/F-box (SCF)-S-phase kinase-associated protein 2 (Skp2) E3 ligase complex Sutterluty et al., 1999; Tsvetkov et al., 1999; Mirza et al., 2004) . In this complex, the F-box component, Skp2 and its cofactor, Cdc kinase subunit 1 (Cks1), provide specificity by targeting substrates, such as p27
Kip1 that has been phosphorylated at residue threonine-187 Sutterluty et al., 1999; Spruck et al., 2001; Kamura et al., 2003; Nakayama et al., 2004) . Structural analysis indicates that p27
Kip1 interacts with both Cks1 and Skp2 (Hao et al., 2005) . Knockout of either Skp2 or Cks1 in mice leads to increased p27
Kip1 levels (Nakayama et al., 2000; Spruck et al., 2001) and, notably, expression of Skp2 and Cks1 is enhanced in several cancers (Gstaiger et al., 2001; Latres et al., 2001; Inui et al., 2003; Shapira et al., 2004) .
Melanoma arises from the transformation of melanocytes and is the deadliest form of skin cancer. We have recently investigated the requirements for cell cycle events in human melanocytes and their dysregulation in melanoma. Human melanocytes are dependent upon adhesion for efficient growth factor activation of ERK1/2, which mediates induction of cyclin D1 and downregulation of p27
Kip1 (Conner et al., 2003; Bhatt et al., 2005) . Mutations in B-RAF, a regulator of the mitogen-activated protein-kinase kinase (MEK)-ERK1/2 pathway, are associated with approximately 70% of melanomas; the most common mutant is B-RAF V600E (Davies et al., 2002; Wellbrock et al., 2004a) . In melanoma cells harboring B-RAF V600E , ERK1/2 activity is adhesion-independent and MEK activity is required for constitutive expression of cyclin D1 and downregulation of p27
Kip1 (Bhatt et al., 2005) . Expression of either B-RAF V600E or a regulatable B-RAF-ER fusion protein in melanocytes bypasses the adhesion and growth factor requirements for ERK1/2 activation, cyclin D1 induction and p27
Kip1 suppression. Thus, mutation in B-RAF subverts the adhesion and growth factor requirements for ERK1/2 controlled G1 cell cycle events. Here, we show that B-RAF controls p27 Kip1 expression in melanoma cells at two levels: mRNA abundance and proteasomal degradation. The latter mechanism is also cyclin D1-dependent and occurs via regulation of Cks1 and Skp2.
Results

Mutant B-RAF is required for cyclin D1 expression and p27
Kip1 downregulation in melanoma cells Two-thirds of cutaneous melanomas have mutations in B-RAF; the most common mutant is B-RAF V600E (Davies et al., 2002) . Expression of B-RAF V600E in human melanocytes enhances cyclin D1 levels and decreases p27
Kip1 expression (Bhatt et al., 2005) . To determine if mutant B-RAF is required for expression of cyclin D1 and p27
Kip1 in melanoma cells, we utilized RNA interference (RNAi) to selectively knockdown B-RAF. Two B-RAF V600E -expressing cell lines, WM793 and WM278, were transfected with a B-RAF V600E -targeting or a control small interfering RNA (siRNA) and cell lysates were analysed by Western blotting. B-RAF levels were efficiently downregulated in response to B-RAF V600E siRNA in both WM793 and WM278 cells compared to control knockdowns (Figure 1a-d) . The mutant B-RAF allele is preferentially amplified in some cases of melanoma (Maldonado et al., 2003) ; such amplification would explain the greater than 50% knockdown with the B-RAF V600E siRNA. Cyclin D1 levels were decreased and p27
Kip1 expression increased concomitant with B-RAF knockdown. Quantitation showed that p27 Kip1 levels were increased 2.5-and 3.1-fold after B-RAF V600E knockdown in WM793 and WM278 cells, respectively (Figures 1b and d) .
To reduce concerns about off-target effects of the B-RAF V600E siRNA, we utilized a second B-RAF siRNA (B-RAF duplex #1) that targets a region distinct from the V600E coding sequence. Knockdown of B-RAF with duplex #1 also reduced cyclin D1 levels and upregulated p27
Kip1 levels in WM793 ( Figure 1e) -expressing WM115 cells (Figure 1f ). These results argue against the possibility that alterations in cyclin D1 and p27
Kip1 are due to off-target siRNA effects. Consistent with previous publications (Hingorani et al., 2003; Karasarides et al., 2004; Sumimoto et al., 2004) , B-RAF knockdown in WM793 cells inhibited cell growth (Figure 1g ). Furthermore, B-RAF knockdown cells showed decreased phosphorylation of Rb protein and expression of cyclin A, two markers of G1 cell cycle progression (Figure 1h) . Together, our results show that B-RAF is required for cyclin D1 expression and p27
Kip1 downregulation in human melanoma cells.
p27
Kip1 expression is enhanced in cyclin D1 knockdown melanoma cells During time course experiments with the MEK inhibitor, U0126, we noted that the increase in p27
Kip1 levels was closely timed to the decrease in cyclin D1 levels ( (Bhatt et al., 2005) and data not shown). To directly address whether cyclin D1 regulates levels of p27
Kip1 in melanoma cells, we used RNAi to specifically knockdown cyclin D1 in WM115 and WM793, which express B-RAF V600D and B-RAF
V600E
, respectively. Upon reduction of cyclin D1 expression, an increase in p27 Kip1 expression was observed in both melanoma cell lines (Figures 2a-d) . Quantitation of p27 Kip1 expression showed a sixfold increase in p27
Kip1 levels in WM115 cyclin D1 knockdown cells (Figure 2b) . A less dramatic 1.5-fold increase in p27
Kip1 was observed in WM793 cyclin D1 knockdown cells owing to the higher basal level of p27 Kip1 (Figure 2d ). Analysis of cell lysates with a phosphospecific antibody to threonine-187 on p27 Kip1 also showed enhanced labeling following cyclin D1 knockdown indicating that the expressed p27
Kip1 is phosphorylated at this site (data not shown). Expression of the p27 Kip1 -related protein, p21
Cip1
, was slightly decreased in WM115 and WM793 cyclin D1 knockdown cells (Figures 2a and c) . In summary, reduction of cyclin D1 levels in human melanoma cells results in an upregulation of p27 Kip1 .
p27
Kip1 mRNA levels are increased in response to B-RAF but not cyclin D1 knockdown To determine whether p27
Kip1 mRNA levels are altered in response to B-RAF and cyclin D1 knockdown, we performed real-time quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR). B-RAF knockdown WM793 cells showed enhanced levels of p27 Kip1 mRNA, although some variation in the extent of the increase was observed corresponding to the efficiency of B-RAF knockdown (Figure 3a) . By contrast, cyclin D1 knockdown WM793 cells exhibited a slight reduction (mean decrease of 16%) in p27
Kip1 mRNA levels ( Figure 3b) . Similarly, p27
Kip1 mRNA levels were not enhanced in cyclin D1 knockdown WM115 cells (data not shown). These results raised the possibility that B-RAF may regulate p27
Kip1 at both the mRNA and protein level. A prominent mechanism involved in regulating p27
Kip1 levels is proteasomal degradation (Slingerland and Pagano, 2000) . Treatment of WM793 cells with the proteasomal inhibitors, ALLN and MG132 (Rock et al., 1994; Brandeis and Hunt, 1996) , increased p27 Kip1 protein expression (Figure 3c ), demonstrating control of p27
Kip1 levels in melanoma cells occurs through the 26S proteasome.
Skp2 expression is enhanced in melanoma cells and downregulated by B-RAF and cyclin D1 knockdown
The SCF Skp2 ubiquitin E3 ligase complex is known to mediate p27 Kip1 degradation in several cell types Sutterluty et al., 1999) . Initially, we analysed levels of Skp2 in serum-starved melanoma cell lines (WM793, WM115, SK-MEL-5 and SK-MEL-28) and normal human epidermal melanocytes (NHEM) by Western blotting. Notably, expression of Skp2 was enhanced in all four human melanoma cell lines compared to NHEM (Figure 4a ). Two Skp2 immunoreactive bands were observed consistent with others' reports Sutterluty et al., 1999; Garriga et al., 2003) .
We have previously shown that serum-starved NHEM express high levels of p27
Kip1 that are downregulated in an adhesion and growth factor-dependent manner (Bhatt et al., 2005) . We next determined whether Skp2 levels were regulated by adhesion and/or growth factors in NHEM. Serum-starved NHEM were replated onto poly-lysine, to which they attach via charge-charge interactions, or fibronectin to which they Kip1 protein levels in cyclin D1 knockdown WM115 cells compared to controls from three independent experiments. p27
Kip1 levels in each experiment were normalized to tubulin expression and the ratio for control samples set as 1. (c) and (d) As above except that WM793 cells were utilized.
adhere via integrins. In some conditions, cells were stimulated with growth factors (basic fibroblast growth factor (bFGF), insulin and phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA)). Skp2 expression was not detected in NHEM replated onto poly-lysine or fibronectin in the absence of growth factors but was increased in cells replated onto fibronectin and stimulated with growth factors for 24 h (Figure 4b ). Growth factor induced Skp2 expression was markedly lower in NHEM on poly-lysine compared to that on fibronectin. By contrast, Skp2 levels in melanoma cells were largely independent of integrin-mediated adhesion as similar 
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Kip1 in melanoma cells KV Bhatt et al levels of Skp2 were observed in melanoma cells plated on fibronectin or poly-lysine, a condition in which tyrosine 397 phosphorylation of focal adhesion kinase (FAK) was reduced ( Figure 4c ).
As p27 Kip1 protein levels were increased after B-RAF and cyclin D1 knockdown, we analysed effects on Skp2 expression. Skp2 levels were reduced by 67 and 81% in B-RAF knockdown WM793 and WM278 cells, respectively (Figures 4d and e) . Additionally Skp2 expression was also decreased by 74% following cyclin D1 knockdown (Figure 4f) . Hence, enhanced expression of Skp2 in melanoma cells is regulated by mutant B-RAF and cyclin D1.
Skp2 is required for downregulation of p27
Kip1 levels in melanoma cells To test the requirement for Skp2 in regulating p27 Kip1 expression in melanoma cells, WM793 were transfected with two Skp2 siRNAs that target distinct regions of the Skp2 mRNA. In response to either duplex, Skp2 expression was significantly decreased in WM793 cells, an effect that was selective as no decrease was observed in the protein levels for Skp1 and cullin 1, other components of the SCF Skp2 complex (Figure 5a ). p27
Kip1 expression was increased upon knockdown of Skp2. Other Cdk inhibitor proteins, p21
Cip1 and p57
Kip2
, are putative targets of the SCF Skp2 complex Spruck et al., 2001; Kamura et al., 2003; Nakayama et al., 2004) ; however, we observed only minor changes in expression of these proteins following Skp2 knockdown in WM793 (Figure 5b ) and WM278 cells (data not shown). Furthermore, Skp2 knockdown did not alter STAT1 levels (Sledz et al., 2003) , indicating that changes in p27
Kip1 levels were not owing to an interferon response (data not shown). Enhanced p27 Kip1 levels following Skp2 knockdown were also observed in WM278 (Figure 5c ) and WM115 (data not shown) demonstrating that Skp2 effects on p27 Kip1 were not restricted to one melanoma cell line.
As a second approach to test the requirement for Skp2 in p27
Kip1 degradation in melanoma cells, we infected WM793 cells with DF-box Skp2 adenovirus. This mutant version of Skp2 contains a deletion of the F-box domain that is responsible for the interaction of Skp2 with Skp1 Bond et al., 2004) . The F-box deleted Skp2 still binds phosphorylated p27
Kip1 but is unable to interact with the SCF complex and thus protects p27
Kip1 from degradation. Expression of DF-box Skp2 in WM793 cells increased p27
Kip1 levels compared to control green fluorescent protein (GFP)-expressing cells (Figure 5d ). The effect of DF-box Skp2 on p27
Kip1 levels was not as dramatic as that observed with Skp2 siRNA likely owing to differences in transduction and transfection efficiencies, and times before onset of activity.
To address if the decrease in Skp2 levels in cyclin D1 knockdown cells was responsible for the increased p27 Kip1 expression, we constitutively expressed wild-type Skp2 in cyclin D1 knockdown cells. WM793 cells were transfected with cyclin D1-specific siRNA and subsequently infected with either wild-type Skp2 or a control GFP adenovirus. Expression of wild-type Skp2 decreased levels of p27
Kip1 in cyclin D1 knockdown cells compared to GFP-expressing cells (Figure 5e ).
Together, these results demonstrate that Skp2 down-regulates p27
Kip1 levels in human melanoma cells. 
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Kip1 in melanoma cells KV Bhatt et al by qRT-PCR ( Figure 6a) ; hence, we investigated the role of Cks1, a cofactor for Skp2 that prevents Skp2 auto-ubiquitylation and degradation (Ganoth et al., 2001; Spruck et al., 2001; Wang et al., 2004) . Expression of Cks1 was higher in WM793 and WM115 cells compared to NHEM (Figure 6b ). To test whether reduction in Cks1 expression controlled Skp2 and p27 Kip1 levels in melanoma cells, individual and coknockdowns were performed in WM793 cells. Knockdown of Cks1 alone led to a decrease in Skp2 levels and a concomitant increase in p27 Kip1 (Figure 6c ). Additionally, co-knockdown of Cks1 and Skp2 resulted in a further increase in p27
Kip1 levels compared to Skp2 knockdown alone.
As Cks1 regulated Skp2 levels, we tested for B-RAF and cyclin D1 control of Cks1 expression. In WM793 cells, Cks1 protein levels were downregulated by knockdown of B-RAF or cyclin D1 by 41 and 42%, respectively, as measured by Western blotting (Figure 6d ). Cks1 levels were also regulated by B-RAF in WM115 cells (Figure 6d , right panels). Furthermore, downregulation of Cks1 was observed at the mRNA level following both B-RAF and cyclin D1 knockdown ( Figure 6e ) and after pharmacological inhibition of MEK (Figure 6f ). Together these results show that Cks1 is regulated by B-RAF-MEK signaling and cyclin D1. Additionally they demonstrate that Cks1 controls Skp2, and hence p27
Kip1 levels, in melanoma cells.
Cks1 and Skp2 knockdown inhibit melanoma cell growth
We next analysed the role of Cks1 and Skp2 in the growth of melanoma cells. Individual knockdowns of either Cks1 or Skp2 in WM793 cells markedly decreased cell growth without enhancing apoptosis as measured by cleaved caspase 3 staining (Figure 7a and data not shown). To determine whether p27 Kip1 was able to block melanoma cell proliferation, we transfected WM793 cells with pcDNA3-p27 Kip1(T187A) plasmid. p27 Kip1(T187A) is resistant to ubiquitylation and its expression was controlled by a cytomegalovirus promoter in order to obtain constitutive levels (Montagnoli et al., 1999) . After 24 h, we analysed Ki67 and cyclin A expression, commonly used markers for proliferation and late G1/Sphase entry, by immunofluorescence staining. Seventyfour percent of control GFP-expressing cells stained positively for Ki67. In contrast, only 29% of WM793 cells expressing p27 Kip1(T187A) exhibited marked Ki67 staining (Figure 7b) . Similarly, p27
Kip1(T187A) expression reduced cyclin A staining in WM793 cells compared to GFP controls (data not shown). In summary, these data show that Cks1, Skp2 and p27
Kip1 expression levels regulate melanoma cell growth, most likely through effects on cell proliferation.
Discussion
Cell cycle progression is deregulated in cancerous cells. Alterations in p27
Kip1 warrant particular attention as p27
Kip1 protein levels are reduced in several types of cancer including melanoma (Catzavelos et al., 1997; Loda et al., 1997; Mori et al., 1997; Florenes et al., 1998; Kawana et al., 1998) , and p27
Kip1 heterozygous mice are prone to induced tumor formation (Fero et al., 1998) . B-RAF is mutated in approximately 70% of melanomas (Davies et al., 2002) . Here, we report that mutant B-RAF and cyclin D1 control expression of Cks1 and Skp2, which mediate degradation of p27
Kip1 in melanoma cells.
Initially, we show that mutant B-RAF expression is required for cyclin D1 expression and p27
Kip1 downregulation in melanoma cells. These data complement our previous studies showing that expression of mutant B-RAF is sufficient to upregulate cyclin D1 and downregulate p27
Kip1 in human melanocytes, and that pharmacological inhibition of the B-RAF effector, MEK, has the opposite effects in melanoma cells (Bhatt et al., 2005) . Our findings also provide mechanistic details that underlie others' studies in melanoma cells showing that B-RAF-MEK signaling is necessary for S-phase entry, proliferation and anchorage-independent growth in vitro (Collisson et al., 2003; Hingorani et al., 2003; Karasarides et al., 2004; Sumimoto et al., 2004) , and growth in vivo (Collisson et al., 2003; Sumimoto et al., 2004; Sharma et al., 2005) , and the report that B-RAF V600E transforms mouse melanocytes (Wellbrock et al., 2004b) . It is possible that wild-type B-RAF, which is activated by autocrine growth factor signaling (Satyamoorthy et al., 2003) , may also contribute to the regulation of cyclin D1 and p27 Kip1 in our experiments utilizing siRNA that targets both mutant and wild-type B-RAF. We have previously published that cyclin D1 knockdown inhibits G1-S cell cycle progression in B-RAF V600E -expressing melanoma cells (Bhatt et al., 2005) . Additionally, others have shown that antisensemediated downregulation of cyclin D1 expression in melanoma cell lines reduces their tumorigenicity in vivo (Sauter et al., 2002) . We now show that p27 Kip1 expression is increased concomitant with cyclin D1 knockdown, illustrating the coordinated nature of cell cycle events.
Our results show multiple modes of p27 Kip1 regulation consistent with others' recent studies (Malek et al., 2001; Mirza et al., 2004) . One mechanism whereby B-RAF regulates p27 Kip1 is control of mRNA level. Studies from McMahon and co-workers have shown that activation of C-RAF in NIH3T3 fibroblasts downregulates p27 Kip1 mRNA (Mirza et al., 2004) and MEK inhibition upregulates p27
Kip1 mRNA in some pancreatic cancer cell lines (Gysin et al., 2005) . Studies in melanoma cells have previously observed an increase in p27
Kip1 mRNA in response to culture in fibrillar collagen (Henriet et al., 2000) , although effects on MEK-ERK1/2 signaling were not presented. Although experiments in fibroblasts have implicated a role for PI-3 kinase/Akt signaling in the regulation of p27
Kip1 (Mirza et al., 2004) , we have not observed alterations in p27
Kip1 levels upon treatment with the PI-3 kinase inhibitor, LY294002, in melanoma cell lines (data not shown). Nevertheless, the role of PI-3 kinase/Akt signaling in melanoma cell cycle events warrants further investigation as this pathway is frequently altered (Stahl et al., 2004) . p27 Kip1 levels in melanoma cells are also regulated by the proteasome. Phosphorylation at threonine 187 is permissive for p27
Kip1 degradation (Vlach et al., 1997; Carrano et al., 1999; Sutterluty et al., 1999) . However, as threonine 187-phosphorylated p27
Kip1 levels increased in parallel with total p27
Kip1 (data not shown), we focused on possible defects in the SCF complex containing Skp2 and its cofactor, Cks1, that recognizes phosphorylated p27
Kip1 and targets it for degradation (Ganoth et al., 2001; Spruck et al., 2001) . We demonstrate that B-RAF and cyclin D1 control Skp2 and Cks1 levels in melanoma cells. First, we show that both Skp2 and Cks1 expression is enhanced in human melanoma cells lines compared to melanocytes. Enhanced levels of Skp2 have been associated with several types of human cancer (Gstaiger et al., 2001) and, during the course of our work, have been detected in melanoma tissue sections (Li et al., 2004; Woenckhaus et al., 2005) . Also, Cks1 levels are enhanced in non-small cell lung and colorectal carcinoma (Inui et al., 2003; Shapira et al., 2004) . Second, Skp2 levels are dependent on adhesion and growth factors in human melanocytes, similar to findings in fibroblasts (Carrano and Pagano, 2001) , and inversely correlate with the levels of p27
Kip1 (Bhatt et al., 2005) . Conversely, Skp2 expression in melanoma cells is adhesion-independent, consistent with similar findings on mutant B-RAF signaling and cyclin D1 expression (Conner et al., 2003; Bhatt et al., 2005) . Third, both Skp2 and Cks1 levels are decreased by knockdown of either B-RAF or cyclin D1. The mechanism of B-RAF-cyclin D1 effects on p27
Kip1 appears distinct from the Rb-mediated competition for Skp2 binding that also enhances p27
Kip1 levels (Ji et al., 2004 ) and a non-catalytic role for Cdk2 in the regulation of Skp2-p27
Kip1 complexes 
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Kip1 in melanoma cells KV Bhatt et al (Zhu et al., 2004) . As expression of Skp2 is regulated in a cell cycle-dependent manner (Bashir et al., 2004; Wei et al., 2004) , knockdown of B-RAF or cyclin D1 likely prevents the expression of Skp2 in late G1/S. This notion is consistent with studies by showing that overexpression of p107 downregulates Skp2 levels in fibroblast cells (Rodier et al., 2005) . F-box proteins are known to be intrinsically unstable (Galan and Peter, 1999; Wirbelauer et al., 2000) . We show that Skp2 levels are regulated by Cks1. Our cellbased assays complement previous in vitro studies which indicate that Cks1 may stabilize Skp2 protein by preventing its ubiquitylation and subsequent proteasomal degradation (Wang et al., 2004) . Notably, Skp2 mRNA levels in melanoma cells are not altered by cyclin D1 knockdown (Figure 6a) or by Cks1 knockdown (data not shown). Thus, our data indicate that mutant B-RAF and cyclin D1 control expression of Cks1, which in turn stabilizes Skp2 levels. Regulation of Skp2 through this pathway likely occurs through inhibiting Skp2 ubiquitylation, and may involve the anaphasepromoting complex/cyclosome-Cdh1 complex that is known to degrade Skp2 (Bashir et al., 2004; Wang et al., 2004; Wei et al., 2004) .
Skp2 and Cks1 are required for regulation of p27 Kip1 in cutaneous melanoma cells. This requirement appears to be distinct from reported results in ocular melanomas, such as those derived from the choroids, in which p27 Kip1 degradation may be mediated by calpain (Delmas et al., 2003) . While our studies were in progress, Nakayama co-workers provided evidence that an alternative ubiquitin ligase complex, KPC (Kip1 ubiquitylation-promoting complex) regulates p27
Kip1 degradation in the G1 phase of the cell cycle (Kamura et al., 2004) . Whether this E3 ligase, in addition to Skp2, regulates p27 Kip1 in melanoma is unknown, at present. Depletion of either Cks1 or Skp2 inhibits melanoma cell growth, most likely through effects on proliferation. In agreement, with these findings, knockdown of Skp2 inhibits growth of melanoma cells in vitro and in vivo (Katagiri et al., 2006; Sumimoto et al., 2006) . Cells from Skp2 knockout mice display decreased proliferation but differing conclusions have been reached about the nature of the cell cycle block. Malek and co-workers showed that deficient proliferation in regenerating liver cells from Skp2 (À/À) mice was associated with a G1 arrest and lack of cyclin A induction (Kossatz et al., 2004) . In contrast, Nakayama et al. (2004) showed that mouse embryo fibroblasts derived from Skp2 (À/À) mice had decreased Cdk1 and Cdk2 activity and exhibited a defect in progression through G2/M. Future experiments will analyse the effect of Skp2 and Cks1 knockdown on different stages of the cell cycle in melanoma cells.
In summary, our results show that mutant B-RAF signaling and cyclin D1 regulate Cks1 and Skp2 levels in melanoma cells. This pathway acts jointly with B-RAF control of p27
Kip1 mRNA levels to downregulate p27 Kip1 protein expression. As low p27 Kip1 levels are associated with a poor prognosis in melanoma, our studies demonstrating mechanisms by which mutant B-RAF regulates p27
Kip1 have important implications for control of the cell cycle in this malignancy.
Materials and methods
Melanoma cell culture
Human melanoma cell lines, WM793, WM115 and WM278, were obtained from Dr Meenhard Herlyn (Wistar Institute, Philadelphia) and maintained in modified chemically defined medium (MCDB) 153 medium containing 0.2% (w/v) sodium bicarbonate, 0.5% (v/v) fetal bovine serum and 5 mg/ml insulin. The MEK inhibitor, U0126, was purchased from Cell Signaling Technology (Beverley, MA, USA). ALLN and MG132 were obtained from Calbiochem (La Jolla, CA, USA).
Melanocyte isolation and culture
Neonatal foreskins were obtained according to Albany Medical College Institutional Review Board procedures. NHEM were isolated, as described previously (Conner et al., 2003) , and cultured in MCDB 153 medium (Sigma, St Louis, MO, USA) containing 0.2% (w/v) sodium bicarbonate (Mediatech Inc., Herndon, VA, USA), 0.5% (v/v) fetal bovine serum (HyClone, Logan, UT, USA), 0.05% (v/v) bovine pituitary extract (Invitrogen, Carlsbad, MA, USA), 0.5 mg/ml hydrocortisone (Sigma), 10 mg/ml insulin (Sigma), 1 ng/ml bFGF (BD Biosciences, San Jose, CA, USA), and 8 nM TPA (Calbiochem). Melanocytes were used between passages three and ten for experiments.
RNAi
Melanoma cells (2 Â 10 5 ) were transfected with siRNA (Dharmacon, Lafayette, CO, USA) at a concentration of 25 nM using OligofectAMINE (Invitrogen). For B-RAF knockdowns, two siRNAs were used: B-RAF V600E (GA GAAAUCUCGAUGGAGUGGG) (Calipel et al., 2003) and B-RAF duplex #1 (ACAGAGACCUCAAGAGUAAUU). Cyclin D1 knockdowns were carried out with a SmartPool, as described previously (Bhatt et al., 2005) . Importantly, experiments with individual cyclin D1 siRNA sequences gave the same results. Skp2 knockdowns were performed using individual siRNA sequences: duplex #1 (CAUCUAGA CUUAAGUGAUAUU) and duplex #2 (GGUAUCGC CUAGCGUCUGAUU). Cks1 was knocked down with the following siRNA: (CGACGAGGAGUUUGAGUAUUU). A non-targeting siRNA (Dharmacon) was used as a control. For experiments involving simultaneous knockdowns, melanoma cells were transfected with 25 nM of each individual siRNA to give a final concentration of 50 nM. Cells were transfected for 4 h in serum-free medium following which 1.5 ml of MCDB 153 medium containing 0.2% sodium bicarbonate, 0.5% fetal bovine serum and 5 mg/ml insulin was added. Cells were harvested after 72 h unless otherwise indicated.
Adenoviral infections
WM793 cells were infected with DF-box Skp2 or GFP adenovirus in serum-free MCDB 153 medium. Cells were lysed 48 h post-infection. In some experiments, cyclin D1 knockdown WM793 cells were infected with wild-type Skp2 or GFP adenovirus for 16 h. The wild-type and DF-box Skp2 adenoviruses (Bond et al., 2004) were obtained from Dr Mark Bond (University of Bristol, Bristol, UK). Infection efficiencies were approximately 70%, as judged by GFP fluorescence.
Adhesion experiments
Cell adhesion experiments with melanocytes were performed as described previously (Bhatt et al., 2005) . Briefly, melanocytes were replated in serum-free MCDB 153 medium containing 0.5% (w/v) BSA onto poly-L-lysine (10 mg/ml) or fibronectin (20 mg/ml; BD Biosciences) coated dishes. After 1.5 h, when the cells had attached, growth factors (10 mg/ml insulin, 1 ng/ml basic FGF and 8 nM TPA) were added to some cultures.
qRT-PCR Seventy-two hours post-knockdown, total RNA was extracted from melanoma cells using the PURESCRIPT RNA Isolation kit (Gentra Systems, Minneapolis, MN, USA). RNA (1 mg) was reverse transcribed and 1/20th of the resulting complementary DNA (cDNA) was utilized to detect mRNA abundance with primers for actin (control), B-RAF, Cks1, cyclin D1, p27
Kip1 and Skp2 (see Table 1 for sequences). All primers were designed to give 150-200 base pair products and their specificity was confirmed by melt curve analysis. Reactions were performed using SYBR Green mix and the MyiQ real-time PCR detection system (BioRad, Hercules, CA, USA). Final concentrations of the reaction components were: 50 mM KCl, 20 mM Tris-HCl, (pH 8.4), 0.2 mM of dATP/ dCTP/dGTP/dTTP, 25 U/ml DNA polymerase, 3 mM MgCl 2 and 200 nM of forward and reverse primers. Reaction conditions were: denaturation at 941C for 30 s; annealing at 501C for 30 s and elongation at 721C for 30 s; 40 cycles in total. Relative mRNA levels were calculated using the Comparative C t method (DC t ) (Pfaffl, 2001 ).
Western blotting
Melanoma and melanocyte cell lysates (10-20 mg/lane) were analysed for protein expression by Western blotting with the following primary antibodies: B-RAF (BD-Biosciences; clone 13), cyclin D1 (BD-Biosciences; DCS-6), p27
Kip1 (BDTransduction; clone 57), p21
Cip1 (BD-Biosciences; sx-118), p57
Kip2 (NeoMarkers, Fremont, CA, USA; Ab-5), b-tubulin (Chemicon; KMX), Skp2 (Zymed, South San Francisco; Skp2-8D9), Skp1 (NeoMarkers; Ab-1), cullin1 (NeoMarkers; Ab-2), ERK1/2 (Santa Cruz Biotech., Santa Cruz, CA, USA); K-23); phospho397 FAK (Biosource Int., Camarillo, CA, USA), FAK (BD-Biosciences clone 77), phospho(780)-Rb (Cell Signaling) and cyclin A (Santa Cruz Biotech.; H-432). Western blots were developed using SuperSignal chemiluminescent substrate (Pierce, Rockford, IL, USA) and quantitated with a Fluor-S MultiImager and Quantity-One software (BioRad).
Immunofluorescence Cells were transfected with either pcDNA3-FLAG-p27 Kip1(T187A) (Ishida et al., 2002) or pGreen Lantern1 and replated onto coverslips in serum/growth factor containing medium. Transfection efficiencies were approximately 20%. Cells were formaldehyde fixed, permeabilized and stained with antibodies to Ki67 (NeoMarkers) and p27
Kip1 and appropriate AlexaFluor conjugated secondary antibodies. Fluorescent staining was viewed on an Olympus BX60 microscope equipped for epifluorescence. Images were captured using a Spot charged coupled device camera and processed using deconvolution Slide Book software.
Statistical analysis
Groups of samples were compared using a one-sided Student's t-test using Minitab software. Differences were significant at Po0.05 (*), or Po0.01 (**), as indicated.
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